Deutsche Bank and Others Act as Underwriters for Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2026
0mins
Deutsche Bank Securities, Mizuho Securitie, and Craig-Hallum are acting as the underwriters of this offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MVIS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MVIS
About MVIS
MicroVision, Inc. is a developer and supplier of lidar hardware and software solutions focused on the automotive lidar and advanced driver-assistance systems (ADAS) markets. It is engaged in micro-electromechanical systems (MEMS)-based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms, and machine learning software into its technology to address existing and emerging markets. Its patented laser beam scanning technology combines a MEMS scanning mirror, laser diode light sources, electronics, and optics that are controlled using its system control algorithms. It has developed micro-display concepts and designs for use in head-mounted augmented reality (AR) headsets and developed a 1440i MEMS module supporting AR headsets. Its products include MAVIN N is a MEMS-based long-range sensor capable of small object detection; MOVIA L & MOVIA S is a flash-based short-to mid-range sensor, and MOSAIK Suite is validating vehicle sensors for ADAS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MicroVision Partners with Industrial Leader for Lidar Development
- Agreement Signing: MicroVision has signed a master development agreement with a leading manufacturer in construction and mining equipment, aiming to evaluate and deploy advanced lidar sensing technologies to enhance environmental awareness and obstacle detection in complex industrial settings.
- Initial Deployment Plan: The customer will initially install two Iris lidar sensors on their off-highway trucks, with potential integration of MicroVision's Halo lidar sensors if the collaboration proves successful, thereby enhancing the intelligence and safety of the equipment.
- Stock Price Surge: Following the announcement of the partnership, MicroVision's stock surged 11% on Wednesday, reflecting market recognition of its potential in industrial automation, despite the stock having lost over 55% of its value this year.
- Strategic Portfolio Expansion: In recent years, MicroVision has strengthened its portfolio through acquisitions of assets from Luminar Technologies, Ibeo Automotive Systems, and Scantinel, aiming to further expand its influence in the automotive, security, and defense markets.
See More
Fulcrum, Heron, and MicroVision Stocks Plunge to Record Lows
- Fulcrum Drug Development Halted: Fulcrum Therapeutics saw its stock plunge over 51% to a 52-week low of $2.90 after announcing the discontinuation of its lead sickle cell disease drug pociredir due to FDA concerns about potential cancer risks, leading analysts to lower growth expectations and impacting the company's future prospects.
- Heron Patent Invalidated: Heron Therapeutics' shares fell to a record low of $0.44 following a federal court ruling that invalidated patents related to its cancer-supportive care drug CINVANTI, which could allow generic versions to enter the market sooner, prompting the CEO to announce an appeal and analysts to downgrade the stock to 'Hold'.
- MicroVision Reverse Stock Split Proposal: MicroVision's stock dropped nearly 32% to a 52-week low of $0.40 as the company sought shareholder approval for a reverse stock split proposal aimed at complying with Nasdaq's minimum bid-price requirement, which could significantly affect shareholder equity, while retail sentiment remained 'bearish'.
- Overall Market Reaction: Year-to-date, shares of FULC, HRTX, and MVIS have plunged between 50% and 72%, reflecting investor concerns over the core business prospects of these companies, although retail sentiment for Fulcrum on Stocktwits remains categorized as 'extremely bullish'.
See More
MicroVision Reports Q1 2026 Financial Results with Significant Growth
- Significant Revenue Growth: MicroVision reported Q1 2026 revenue of $0.9 million, a 50% year-over-year increase, primarily driven by the $33 million acquisition of Luminar lidar assets, highlighting the company's strong growth potential in augmented reality.
- Gross Margin Surge: The gross margin jumped from 7% in Q1 2025 to 39%, reflecting a better product mix from the acquired Luminar sensor inventory, indicating early integration benefits and enhancing competitive positioning in the market.
- Net Loss Exceeds Expectations: Despite revenue growth, MicroVision reported a net loss of $0.08 per share, wider than the expected $0.04 loss, attributed to significant restructuring costs and a 15% reduction in global workforce, showcasing challenges during the company's transformation.
- Optimistic Future Outlook: Management reaffirmed its full-year 2026 revenue target of $10 million to $15 million, expecting significant commercial traction in the second half of the year, while raising gross margin guidance to 35%-40%, reflecting positive outcomes from supply chain negotiations.
See More
MicroVision Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: MicroVision reported $0.9 million in revenue for Q1, a 50% increase compared to the same period in 2025, with 75% of this revenue attributed to sensor sales from the Luminar acquisition, demonstrating the direct financial benefits of the acquisition.
- Margin Improvement: The gross margin for Q1 was 39%, a substantial increase from 7% in the same quarter last year, reflecting the company's success in negotiating supply agreements and optimizing its product mix, which is expected to further enhance profitability going forward.
- Cash Flow Enhancement: The cash flow from operations plus CapEx for Q1 was $16.6 million, with total cash and cash equivalents amounting to $46.1 million, indicating positive progress in integration activities and cost synergies, thereby strengthening financial flexibility.
- Optimistic Outlook: The company maintains its revenue projection for 2026 at $10 million to $15 million and has lowered its cash burn guidance to approximately $60 million, signaling management's confidence in revenue growth in the second half of the year.
See More
Microvision Reports Q1 2026 Earnings Highlights
- Revenue Growth: Microvision reported Q1 2026 revenue of $0.9 million, reflecting a 50% year-over-year increase, indicating signs of recovery in the market despite ongoing financial challenges.
- Rising Operating Expenses: Total operating expenses for Q1 2026 reached $23.9 million, up from $14.1 million in Q1 2025, primarily driven by costs associated with acquisitions and integration activities, highlighting the company's aggressive investment in business expansion.
- Adjusted EBITDA Loss: The adjusted EBITDA loss for Q1 2026 was $17.2 million, compared to a $10.7 million loss in Q1 2025, indicating that the company still faces challenges in profitability, particularly against the backdrop of high operating costs.
- Cash Flow Situation: As of the end of Q1 2026, Microvision had $46.1 million in cash and cash equivalents, a significant decrease from $74.8 million on December 31, 2025, reflecting increased cash consumption pressures during operations.
See More
Microvision Q4 Revenue Plummets 88%, Downgraded to Hold
- Revenue Decline: Microvision's Q4 revenue plummeted 88% year-on-year to $0.2 million, with a loss per share of $0.12, significantly missing analysts' expectations of $3 million and a loss of $0.05 per share, indicating severe financial challenges ahead.
- Analyst Downgrade: D. Boral Capital analyst Jesse Sobelson downgraded Microvision from 'Buy' to 'Hold', citing ongoing uncertainty regarding near-term sales growth and increased spending pressures, which have negatively impacted market confidence.
- Poor Financial Performance: The company reported a quarterly net loss of $37.8 million, up from $31.2 million in the prior-year quarter, reflecting significant non-cash impairment and inventory charges, raising further concerns about its financial health among investors.
- Liquidity Position: Microvision ended the year with approximately $74.8 million in cash and investment securities, and in February 2026, it bolstered its balance sheet by issuing $43 million in senior secured convertible notes under an agreement with High Trail Capital, enhancing its financial stability.
See More
MicroVision Partners with Industrial Leader for Lidar Development
- Agreement Signing: MicroVision has signed a master development agreement with a leading manufacturer in construction and mining equipment, aiming to evaluate and deploy advanced lidar sensing technologies to enhance environmental awareness and obstacle detection in complex industrial settings.
- Initial Deployment Plan: The customer will initially install two Iris lidar sensors on their off-highway trucks, with potential integration of MicroVision's Halo lidar sensors if the collaboration proves successful, thereby enhancing the intelligence and safety of the equipment.
- Stock Price Surge: Following the announcement of the partnership, MicroVision's stock surged 11% on Wednesday, reflecting market recognition of its potential in industrial automation, despite the stock having lost over 55% of its value this year.
- Strategic Portfolio Expansion: In recent years, MicroVision has strengthened its portfolio through acquisitions of assets from Luminar Technologies, Ibeo Automotive Systems, and Scantinel, aiming to further expand its influence in the automotive, security, and defense markets.
See More
Fulcrum, Heron, and MicroVision Stocks Plunge to Record Lows
- Fulcrum Drug Development Halted: Fulcrum Therapeutics saw its stock plunge over 51% to a 52-week low of $2.90 after announcing the discontinuation of its lead sickle cell disease drug pociredir due to FDA concerns about potential cancer risks, leading analysts to lower growth expectations and impacting the company's future prospects.
- Heron Patent Invalidated: Heron Therapeutics' shares fell to a record low of $0.44 following a federal court ruling that invalidated patents related to its cancer-supportive care drug CINVANTI, which could allow generic versions to enter the market sooner, prompting the CEO to announce an appeal and analysts to downgrade the stock to 'Hold'.
- MicroVision Reverse Stock Split Proposal: MicroVision's stock dropped nearly 32% to a 52-week low of $0.40 as the company sought shareholder approval for a reverse stock split proposal aimed at complying with Nasdaq's minimum bid-price requirement, which could significantly affect shareholder equity, while retail sentiment remained 'bearish'.
- Overall Market Reaction: Year-to-date, shares of FULC, HRTX, and MVIS have plunged between 50% and 72%, reflecting investor concerns over the core business prospects of these companies, although retail sentiment for Fulcrum on Stocktwits remains categorized as 'extremely bullish'.
See More
MicroVision Reports Q1 2026 Financial Results with Significant Growth
- Significant Revenue Growth: MicroVision reported Q1 2026 revenue of $0.9 million, a 50% year-over-year increase, primarily driven by the $33 million acquisition of Luminar lidar assets, highlighting the company's strong growth potential in augmented reality.
- Gross Margin Surge: The gross margin jumped from 7% in Q1 2025 to 39%, reflecting a better product mix from the acquired Luminar sensor inventory, indicating early integration benefits and enhancing competitive positioning in the market.
- Net Loss Exceeds Expectations: Despite revenue growth, MicroVision reported a net loss of $0.08 per share, wider than the expected $0.04 loss, attributed to significant restructuring costs and a 15% reduction in global workforce, showcasing challenges during the company's transformation.
- Optimistic Future Outlook: Management reaffirmed its full-year 2026 revenue target of $10 million to $15 million, expecting significant commercial traction in the second half of the year, while raising gross margin guidance to 35%-40%, reflecting positive outcomes from supply chain negotiations.
See More
MicroVision Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: MicroVision reported $0.9 million in revenue for Q1, a 50% increase compared to the same period in 2025, with 75% of this revenue attributed to sensor sales from the Luminar acquisition, demonstrating the direct financial benefits of the acquisition.
- Margin Improvement: The gross margin for Q1 was 39%, a substantial increase from 7% in the same quarter last year, reflecting the company's success in negotiating supply agreements and optimizing its product mix, which is expected to further enhance profitability going forward.
- Cash Flow Enhancement: The cash flow from operations plus CapEx for Q1 was $16.6 million, with total cash and cash equivalents amounting to $46.1 million, indicating positive progress in integration activities and cost synergies, thereby strengthening financial flexibility.
- Optimistic Outlook: The company maintains its revenue projection for 2026 at $10 million to $15 million and has lowered its cash burn guidance to approximately $60 million, signaling management's confidence in revenue growth in the second half of the year.
See More
Microvision Reports Q1 2026 Earnings Highlights
- Revenue Growth: Microvision reported Q1 2026 revenue of $0.9 million, reflecting a 50% year-over-year increase, indicating signs of recovery in the market despite ongoing financial challenges.
- Rising Operating Expenses: Total operating expenses for Q1 2026 reached $23.9 million, up from $14.1 million in Q1 2025, primarily driven by costs associated with acquisitions and integration activities, highlighting the company's aggressive investment in business expansion.
- Adjusted EBITDA Loss: The adjusted EBITDA loss for Q1 2026 was $17.2 million, compared to a $10.7 million loss in Q1 2025, indicating that the company still faces challenges in profitability, particularly against the backdrop of high operating costs.
- Cash Flow Situation: As of the end of Q1 2026, Microvision had $46.1 million in cash and cash equivalents, a significant decrease from $74.8 million on December 31, 2025, reflecting increased cash consumption pressures during operations.
See More
Microvision Q4 Revenue Plummets 88%, Downgraded to Hold
- Revenue Decline: Microvision's Q4 revenue plummeted 88% year-on-year to $0.2 million, with a loss per share of $0.12, significantly missing analysts' expectations of $3 million and a loss of $0.05 per share, indicating severe financial challenges ahead.
- Analyst Downgrade: D. Boral Capital analyst Jesse Sobelson downgraded Microvision from 'Buy' to 'Hold', citing ongoing uncertainty regarding near-term sales growth and increased spending pressures, which have negatively impacted market confidence.
- Poor Financial Performance: The company reported a quarterly net loss of $37.8 million, up from $31.2 million in the prior-year quarter, reflecting significant non-cash impairment and inventory charges, raising further concerns about its financial health among investors.
- Liquidity Position: Microvision ended the year with approximately $74.8 million in cash and investment securities, and in February 2026, it bolstered its balance sheet by issuing $43 million in senior secured convertible notes under an agreement with High Trail Capital, enhancing its financial stability.
See More
